Insuline-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats by Gil i Santano, Joan et al.
THE JOURNAL OF BIOLOGICAL CHEMISTRY 
0 1988 by The American Society for Biochemistry and Molecular Biology, Inc. 
Vol. 263, No. 4, Issue of February 5, pp. 1868-1871, 1988 
Printed  in U.S.A. 
Insulin-like Effects of  Vanadate  on  Glucokinase Activity and  Fructose 
2,6-Bisphosphate Levels in the Liver of  Diabetic  Rats* 
(Received for publication, March 18, 1987) 
Joan GilS, Montserrat Miralpeix, Jose Cameras, and  Ramon Bartrons 
From  the  Unitat  de  Bioquimica, Facultat de  Medicina,  Uniuersitat  de Barcelona, Zona  Uniuersitaria de Pedralbes, 
08028 Barcelona, Spain 
Streptozotocin diabetic rats showed more than a 4- 
fold increase in blood glucose levels, whereas hepatic 
glycogen, fructose 2,6-bisphosphate concentration, 
and 6-phosphofructo-2-kinase activity were de- 
creased. The “total” 6-phosphofructo-2-kinase and the 
“active” (nonphosphorylated) form of the enzyme were 
decreased to a different  extent, resulting in a fall of 
the “active”J“tota1” activity ratio. Vanadate adminis- 
tration for a 2-week period restored the altered values 
in the diabetic rats without modifying significantly in 
the control animals any of the parameters studied. 
Glucokinase activity was essentially lacking in the 
diabetic animals, and vanadate treatment restored the 
activity to about 65% of its control value, a good cor- 
relation between the recovery of the enzyme and the 
blood glucose level being observed. These results show 
an insulin-like  effect of vanadate in the whole animal 
and suggest that insulin and vanadate possess similar 
actions on hepatic intracellular events. 
Although the effects of vanadium have received increased 
attention (for review see Refs. 1 and 2), its function still 
remains unclear. Biochemically, vanadium compounds gen- 
erally affect systems that utilize ATP and enzymes that 
catalyze phosphotransferase  and  phosphohydrolase  reactions 
In intact cells, vanadium compounds possess insulin-like 
effects. They mimic both the glucose transport-dependent 
and  the  intracellular  actions of insulin in isolated  rat  adipo- 
cytes (9-14) and  in  skeletal muscle  (15). They  enhance gly- 
cogen synthesis in rat  hepatocytes (16) and  inhibit ACTH’- 
induced lipolysis in  rat  adipocytes (11). Furthermore,  vana- 
date elicits  a  mitogenic response  in  human  fibroblasts  and  in 
the  3T3  and  3T6 cell lines (17, 18),  and  it  interacts ynergis- 
tically  with  growth factors  such as epidermal growth factor, 
insulin,  and  insulin-like growth factor I1 (17-19). 
In  the whole animal, Heyliger et al. (20)  have  shown that 
oral  administration of vanadate  to diabetic rats normalized 
the high blood glucose concentration  and  prevented  the  de- 
cline in  cardiac  performance due to  diabetes, suggesting that 
vanadate  has  an  insulin-like ffect on glucose metabolism “in 
uiuo.” 
In  diabetes  there  are  profound metabolic changes  in liver 
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carbohydrate metabolism, which likely flow primarily from 
altered hormonal regulation of metabolic  signals such as 
fructose-2,6-Pz.  This bisphosphorylated  metabolite, by acting 
as allosteric  effector of both  phosphofructokinase  and  fruc- 
tose-l,6-bisphosphatase, regulates the flux over the glyco- 
lytic/gluconeogenic pathways,  and  thereby  it  can lso control 
hepatic lipid  metabolism and ketogenesis (21-24). The  con- 
centration of fructose-2,6-P2 in liver is determined by nutri- 
tional  and hormonally  induced  changes in  the  activity of the 
bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6- 
bisphosphatase responsible  for its  synthesis  and  degradation. 
The regulation of the enzyme is a complex function of both 
the influence of substrates and effectors and its covalent 
modification  via phosphorylation/dephosphorylation (21-24). 
Phosphorylation by the cyclic AMP-dependent  protein  kinase 
results  in  inhibition of the  kinase  and  activation of the bis- 
phosphatase, while dephosphorylation  results  in opposite 
changes in the two activities (25). In addition, the total 
enzymatic activity is dependent  on  the  rates of synthesis  and 
degradation of the enzyme  (26). 
It  has  been found that  in  the liver of alloxan  diabetic rats 
the levels of fructose-2,6-Pz and 6-phosphofructo-2-kinase 
activity  are decreased (27),  and  the degree of phosphorylation 
of the bifunctional enzyme is increased, a good correlation 
between fall of hepatic  fructose-2,6-P2,  ketonemia,  and gly- 
cemia  being  observed  (28). Insulin  administration normalizes 
all  the values (27, 28). 
The present work was undertaken to study the effects 
produced  by vanadate  administration  on glycemia and  on  the 
levels of glycogen, fructose-2,6-Pz and 6-phosphofructo-2- 
kinase  activity  in  the liver of diabetic rats. I t  also reports  the 
effect of vanadate administration on the induction of the 
hepatic glucokinase activity, which is  almost  absent  in  dia- 
betes (29). 
EXPERIMENTAL  PROCEDURES 
Chemicals-Sodium orthovanadate (Na3V04) was obtained from 
Fisher.  Enzymes  and biochemical reagents were from either  Boehrin- 
ger Mannheim  or Sigma. All other chemicals were of analytical grade. 
Treatment of Animals-The general features of the experiment 
were as described by Heyliger et al. (20).  Male  Sprague-Dawley rats 
weighing 190-210 g were made  diabetic by intravenous injection of 
streptozotocin (60 mg/kg) dissolved in 0.5 ml of 50 mM sodium citrate, 
0.15 M NaC1, pH 4.5. Controls received buffer injections only. One 
week after  diabetes  induction blood samples were collected from  the 
tail vein and were determined for concentration of glucose. The 
animals were judged diabetics if blood glucose levels exceeded 350 
mg/dl and were randomly divided into four groups: control;  vanadate- 
treated  controls; streptozotocin-injected; and  vanadate-treated  strep- 
tozotocin-injected. The controls  and  the streptozotocin-injectedgroup 
drank a 0.5 g/100 ml NaCl  solution. The vanadate-treated  animals 
group drank a 0.5 g/100 ml NaCl  solution containing sodium ortho- 
vanadate (0.7 mg/ml) prepared freshly everyday. The vanadate  intake 
was 77 * 10 mg/kg/day for the  controls  and  61 f 8 mg/kg/day for 
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TABLE I 
Body  weight,  food and fluid intake, and liver vanadium content of experimental rats 
General features of the experiment are described under  “Experimental Procedures.” Results are expressed as 
means f S.E. for the number of animals in parentheses, and  the significance of differences was tested by Student’s 
t test: * p < 0.05, ** p < 0.01, *** p < 0.001 versus untreated controls. 
Group Body weight Food intake Fluid intake Liver  vanadium 
g gf day ml f day &?I&? 
Untreated (5) 320 f 4 24 f 0.6  41 f 5 <0.05 
Vanadate-treated (8) 296 f 10* 20 f 2* 23 f 3* 0.94 f 0.10*** 
Untreated (8) 261 f 12*** 45 f 2***  268 f la*** <0.05 




Effects of diabetes and vanadate administration on blood  glucose and 
on the hepatic levels of glycogen and fructose-2,6-P2 
General features of the experiment are described under “Experi- 
mental Procedures.” Results are expressed as means f S.E. for the 
number of animals  in  parentheses, and  the significance of differences 
was tested by Student’s  t  test: *** p < 0.001  uersus untreated controls. 
Group Blood glucose Glycogen Fructose-S,B-P, 
mgl dl w f g  nrnollg 
Untreated (5) 116 & 7 41.8 f 4.3  8.6 f 1.2 
Vanadate-treated (8) 104 f 6 44.4 f 3.4  6.7 f 1.1 
Untreated (8) 486 f 25***  17.8 & 2.2*** 0.5 f 0.1*** 
Vanadate-treated (11) 125 f 5 45.7 * 2.6  11.9 f 1.5 
Control 
Streptozotocin-injected 
the diabetic rats. Diabetes was assessed periodically by a test for 
glucosuria (UrotronR from Boehringer Mannheim). The animals were 
killed by decapitation when the glucosuria levels of the vanadate- 
treated diabetic group were normalized (2 weeks after the beginning 
of vanadate treatment). Blood samples were collected at  the time of 
the death, and  the livers were  removed and fastly freeze-clamped in 
liquid N,. 
Assays of Metabolites and Enzymes-Fructose-2,6-P2 was extracted 
and measured as described in Ref.  30. The “total” 6-phosphofructo- 
2-kinase activity and  the “active” form of the enzyme corresponding 
to  the activity of the nonphosphorylated form of the enzyme were 
measured as described in Ref. 31 on the basis of their different kinetic 
properties (32). Liver samples were homogenized in 20 volumes of 
ice-cold 20 mM Pi, 10 mM EDTA, 100 mM KF, 1 mM dithiothreitol, 
pH 7.1, and centrifuged at  27,000 x g for 15 min at 4  “C.  Portions of 
the resulting supernatants were incubated for 10 min at 30 “C in the 
presence of the constituents described below in  a final volume of  0.25 
ml. 6-Phosphofructo-2-kinase was assayed in  the presence of 5 mM 
ATP, 7 mM MgC12, and 100 mM KCl. Furthermore, 50 mM Tris, 1 
mM Pi, 5 mM fructose-6-P, and 17.5 mM glucose-6-P were also present, 
and  the pH was adjusted to 8.5 for determination of the  total activity; 
50 mM Mes, 5 mM Pi, 1 mM fructose-6-P, and 3.5 mM glucose-6-P 
were present and  the  pH was adjusted to 6.6 for the determination of 
the active form of enzyme. Glucokinase activity was calculated as  the 
difference between the glucose phosphorylation capacity at 100 and 
0.5 mM glucose, measured using the continuous assay described by 
Davidson and Arion (33). One unit of activity is defined as  the amount 
of enzyme that transforms 1 @mol of substrate/min. Blood  glucose 
was assayed  as described in Ref.  34. Liver glycogen  was isolated as 
described in Ref. 35, and  the amount of glucose produced by acid 
hydrolysis was determined as in Ref. 34. Vanadium was extracted 
and measured as described in Ref. 36. 
RESULTS 
The four groups of animals used in this study showed 
different fluid and food intake, as summarized in Table I. 
Body  weights of the  diabetic  rats were significantly lower than 
body weights of the  controls.  The fluid and  the food intake of 
the  diabetic  vanadate-untreated  rats were larger than  those 
of the  control  rats.  Animals  that  drank  the  vanadate  solution 
consumed significantly  less  fluid and food than  control  ani- 
mals. Similar results were reported by Heyliger et al. (20). 
The  content of vanadium  in  the liver of untreated  animals 
was less than 0.05 pg/g, while the  vanadate-treated  animals 
showed values of 1 pg/g (Table  I). 
The animals made  diabetic  with streptozotocin showed 
more than a 4-fold increase in blood glucose levels and a 60% 
decrease in hepatic glycogen concentration (Table 11). In 
contrast, glycemia and  hepatic glycogen concentration of the 
diabetic vanadate-treated  rats were not significantly different 
from those of the  controls. Liver  fructose-2,6-P2 concentration 
decreased to  about  6% of the  control values  in the diabetic 
untreated  animals,  and  the  treatment with vanadate  restored 
the  control levels of this metabolite. Administration of vana- 
date  to  control  rats  did  not modify significantly either the 
blood glucose concentration or the  hepatic glycogen and  fruc- 
tose-2,6-P2 levels. 
Table I11 summarizes  the changes  induced by diabetes  and 
by vanadate  treatment  in  the  hepatic glucokinase activity  and 
in the  total  and active (nonphosphorylated)  6-phospho- 
fructo-2-kinase activities. It also summarizes  the changes in 
the  active/total 6-phosphofructo-2-kinase activity  ratio, 
which  reflects the degree of phosphorylation of the bifunc- 
tional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bis- 
phosphatase (31, 32). As shown, both  the  total  and  the active 
6-phosphofructo-2-kinase activities were significantly de- 
creased in the diabetic animals. However, the decrease pro- 
duced in  the  active form of the enzyme was higher than  that 
produced in  the  total 6-phosphofructo-2-kinase activity, re- 
sulting in a fall in the active/total activity ratio. Vanadate 
treatment of the diabetic rats restored both  the  total  and  the 
active 6-phosphofructo-2-kinase activities. In  the diabetic an- 
imals glucokinase activity was essentially  lacking, and  vana- 
date treatment restored the activity to about 65% of the 
control value. Treatment of the  control  rats with vanadate 
did  not modify any of the  activities measured. 
As shown in Fig. 1, there is a good correlation  between the 
hepatic glucokinase activity  and  the severity of the diabetes, 
estimated by the blood glucose level. In order to  obtain  par- 
tially recovered values of glucokinase,  four  diabetic vanadate- 
treated  animals were killed when glucosuria was still  present. 
These animals had normalized their hepatic glycogen and 
fructose-2,6-P2 levels. 
DISCUSSION 
The results herein reported clearly show that vanadate 
mimics insulin effects in uiuo, reducing the high blood glucose 
and  restoring glycogen and  fructose-2,6-P2 levels, and gluco- 
kinase  and 6-phosphofructo-2-kinase activities in  the liver of 
diabetic animals.  The mechanism by which vanadate restores 
glycemia is probably related to the hepatic effects of the 
compound, in  addition  to  those  reported  in  peripheral  tissues 
(9-16). Previous  results (20) exclude an  indirect mechanism 
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TABLE I11 
Effects of diabetes  and  vanadate  administration on hepatic  glucokinose  and 6-phosphofructo-2-kinose activities 
General  features of the experiment are described under “Experimental  Procedures.” Results are expressed as 
means f S.E. for the number of animals in parentheses,  and the significance of differences was tested by Student’s 
t test * p < 0.05, ** p < 0.01, *** p < 0.001 versus untreated controls. 
6-Phosphofructo-2-kinase 
Group Glucokinase 
Active  Total Activity ratio 
unitslg milliunitslg 
Untreated 3.18 f 0.28 (5) 4.0 f 0.40 (5) 6.2 f 0.63 (5) 0.64 f 0.08 (5) 
Vanadate-treated 2.74 f 0.15 (8) 4.3 f 0.51 (8) 6.7 f 0.46 (8) 0.64 f 0.05 (8) 
Untreated 0.05 f 0.01*** (8) 0.9 f 0.17*** (4) 3.3 f 0.70* (4) 0.29 f 0.01** (4) 
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FIG. 1. Correlation between glycemia and hepatic glucoki- 
nase activity. Each point corresponds to one animal. The groups 
were described under “Experimental Procedures”: 0, controls; ., 
vanadate-treated controls; 0, streptozotocin-injected; 0, streptozo- 
tocin-injected and vanadate-treated. Four streptozotocin-injected 
vanadate-treated animals were killed when glucosuria levels were 
between diabetic and normal values (A). 
mediated by an  increase  in  insulin  secretion. 
I t  is believed that  the  modulation of glucokinase activity, 
which  plays  a  major  role in  the  maintenance of glucose ho- 
meostasis (29), arises from changes in the amount of the 
enzyme present  within  the cell. Both  studies in  vivo (29,  37) 
and using primary  cultures of rat  hepatocytes (38, 39) have 
shown that the induction of glucokinase by insulin is the 
result of an increase in  the  rate of synthesis of the enzyme. 
In  streptozotocin-induced  diabetic  rats  the low levels of glu- 
cokinase  synthesis  and  activity  correlated  with a low level of 
mRNA coding  for  glucokinase  (40). Administration of insulin 
increased  translatable glucokinase mRNA  and  enhanced  the 
rate of synthesis  and  the  activity of the enzyme  (29, 37, 40). 
Our  results show that,  similar  to  insulin,  vanadate  treatment 
restores the decreased glucokinase activity in the liver of 
diabetic  rats.  Vanadate could develop this  insulin-like effect 
by  inducing the  synthesis of the enzyme. This is also  probably 
true for the increase in the total 6-phosphofructo-2-kinase 
activity of vanadate-treated diabetic rats. 
The restoration of the active/total 6-phosphofructo-2-ki- 
nase  activity  ratio produced  by vanadate could be explained 
by a  decrease in  the degree of phosphorylation of the bifunc- 
tional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bis- 
phosphatase.  Such a  decrease would result  in  activation of its 
kinase  and  inhibition of its  bisphosphatase  activities,  and  as 
a consequence fructose-2,6-Pz  concentration would increase 
(21-25). Similar effects have been obtained by insulin  treat- 
ment of diabetic rats (27, 28,41).  The increase  in the  hepatic 
concentration of fructose-2,6-P,, by acting on the enzymes 
involved in the fructose-6-P/fructose-1,6-Pz cycle (21-24), 
would shift  the  predominating gluconeogenic flux of diabetes 
to  the glycolytic flux of the  vanadate-treated  animals. 
The effect of vanadate on fructose-2,6-Pz concentration 
cannot be explained by a direct  action  on  6-phosphofructo-2- 
kinase/fructose-2,6-bisphosphatase activity, since it  has been 
recently reported  that “in vitro” vanadate  inhibits  the kinase 
activity of the purified bifunctional enzyme without modifying 
its  phosphatase  activity (8). The discrepancies  between the i n  
vivo and i n  vitro experiments could be explained by the 
distinct effects of the  different  forms of vanadium  (vanadate 
and  vanadyl).  It  is known that  vanadate  enters cells by the 
anion  transport mechanism and  it is reduced to  vanadyl  ions 
(1, 2). It  has been suggested that  the form of vanadium with 
insulin-like effects  observed in whole cell experiments  is  the 
vanadyl ion, whereas vanadate acts as an inhibitor of the 
formation of phosphoprotein  intermediates (9-11, 42). 
Diabetic animals possess low hepatic glycogen content,  and 
the  activation of glycogen synthase  and  accumulation of gly- 
cogen in response to glucose are impaired in livers and  hepa- 
tocytes of diabetic rats.  The  exact  nature of the defect has 
not been established,  although  the decrease in  synthase  phos- 
phatase activity emerges as a decisive event (43, 44). In 
agreement with the  stimulation of glycogen synthesis by van- 
adate in isolated rat hepatocytes found by others (16), the 
results now reported show that  vanadate  treatment of diabetic 
rats  restores  the  hepatic levels of glycogen, possibly through 
activation of glycogen synthase  as  demonstrated  in  other c lls 
(12, 13).  A recent  report of Bosch et al. (45)  describes inacti- 
vation of glycogen synthase  and  activation of glycogen phos- 
phorylase by vanadate  in isolated rat hepatocytes,  concluding 
that  in liver vanadate does not have insulin-like activity. The 
discrepancies  between these  results (45) and  both  those from 
Tolman et al. (16) and  the  results  herein  reported could be 
explained through  the following facts: ( a )  the  different effects 
of vanadyl  and  vanadate,  as described above; ( b )  the influence 
of the period of treatment  in  the  different  experimental  ap- 
proaches; ( c )  the  accumulation of vanadate inside the cells, in 
addition  to vanadyl, when high concentrations of vanadate 
are used (42).  In our experimental  conditions  the  concentra- 
tion of vanadium  in  the liver of treated  animals  attains values 
of 1 Fg/g (Table  I), corresponding to  about 20 nmol/g vana- 
dium. 
The cellular mechanisms of vanadate effects are  not fully 
understood,  although several biochemical actions might ex- 
plain its insulin-like effects. Vanadate, as well as insulin, 
increases the autophosphorylation and the tyrosine kinase 
activity of the insulin receptor (12, 13). However, a recent 
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report proposes that vanadate  stimulates glucose transport  in 
adipocytes acting at a level distal to  the insulin receptor (14). 
It could also act by increasing phosphorylation of other key 
proteins by either activation of the tyrosine kinase (46) or 
inhibition of the phosphotyrosine phosphatase (47) activities. 
The spontaneous esterification of tyrosine residues with van- 
adate could  be an alternative mechanism of vanadate  actions 
(48). In addition, vanadium compounds could act by mediating 
changes in the concentration of cyclic AMP (1, 2) and Ca2+ 
ions (49). 
In conclusion, the results herein and elsewhere reported 
(20) show an insulin-like effect of vanadate in the whole 
animal  and suggest that insulin and vanadate possess similar 
actions on hepatic intracellular events. However, further  stud- 
ies are required to elucidate the mechanism of the cellular 
actions of vanadate. This information could provide valuable 
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